Continued process verification (CPV) of legacy products in the biopharmaceutical industry

The foundational document Continued process verification (CPV): An industry position paper with an example plan published in 2014 describes how to implement CPV. This helped companies accelerate the implementation of CPV by 30% and decreased investigation times by up to 20%, delivering a real fiscal saving for many member companies.

But what is the best way to implement CPV across across a portfolio of legacy products, the vast majority of the of the industry’s portfolio?

This guidance helps companies understand the best strategy to take and more specifically how to:

  • Create efficient and effective plans for legacy products and links to QA systems
  • Approach implementation across multiple sites
  • Deal with discovery, disclosure and regulatory reporting.

Attached Files

File
Continued process verification of legacy products in the biopharmaceutical industry 2018.pdf
Preview
Free registration is required to access this download

  • Version
  • Download 495
  • File Size 1.06 MB
  • File Count 1
  • Create Date 26th June 2018
  • DOI https://doi.org/10.46220/2018DS001
  • Last Updated